The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. 1995

P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
Tumor Immunology Programme, German Cancer Research Center, Heidelberg.

The heterodimeric alpha 4 integrins alpha 4 beta 7 lymphocyte Peyer's patch adhesion molecule ([LPAM]-1) and alpha 4 beta 1 (very late antigen-4) are cell surface adhesion molecules involved in lymphocyte trafficking and lymphocyte-cell and matrix interactions. Known cellular ligands include vascular cell adhesion molecule (VCAM)-1, which binds to alpha 4 beta 1 and alpha 4 beta 7, and the mucosal addressin cell adhesion molecule (MAdCAM)-1, which binds to alpha 4 beta 7. Here we show that the alpha 4 chain of these integrins can itself serve as a ligand. The alpha 4 chain, immunoaffinity purified and immobilized on glass slides, binds thymocytes and T lymphocytes. Binding exhibits divalent cation requirements and temperature sensitivity which are characteristic of integrin-mediated interactions, and is specifically inhibited by anti-alpha 4 integrin antibodies, which exert their effect at the cell surface. Cells expressing exclusively alpha 4 beta 7 (TK-1) or alpha 4 beta 1 (L1-2) both bound avidly, whereas alpha 4-negative cells did not. A soluble 34-kD alpha 4 chain fragment retained binding activity, and it inhibited lymphocyte adhesion to alpha 4 ligands. It has been shown that alpha 4 integrin binding to fibronectin involves an leucine-aspartic acid-valine (LDV) motif in the HepII/IIICS region of fibronectin (CS-1 peptide), and homologous sequences are important in binding to VCAM-1 and MAdCAM-1. Three conserved LDV motifs occur in the extracellular sequence of alpha 4. A synthetic LDV-containing alpha 4-derived oligopeptide supports alpha 4-integrin-dependent lymphocyte adhesion and blocks binding to the 34-kD alpha 4 chain fragment. Our results suggest that alpha 4 beta 7 and alpha 4 beta 1 integrins may be able to bind to the alpha 4 subunit on adjacent cells, providing a novel mechanism for alpha 4 integrin-mediated and activation-regulated lymphocyte interactions during immune responses.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015815 Cell Adhesion Molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis. Cell Adhesion Molecule,Intercellular Adhesion Molecule,Intercellular Adhesion Molecules,Leukocyte Adhesion Molecule,Leukocyte Adhesion Molecules,Saccharide-Mediated Cell Adhesion Molecules,Saccharide Mediated Cell Adhesion Molecules,Adhesion Molecule, Cell,Adhesion Molecule, Intercellular,Adhesion Molecule, Leukocyte,Adhesion Molecules, Cell,Adhesion Molecules, Intercellular,Adhesion Molecules, Leukocyte,Molecule, Cell Adhesion,Molecule, Intercellular Adhesion,Molecule, Leukocyte Adhesion,Molecules, Cell Adhesion,Molecules, Intercellular Adhesion,Molecules, Leukocyte Adhesion

Related Publications

P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
July 2002, The Journal of pharmacology and experimental therapeutics,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
February 2004, Bioorganic & medicinal chemistry letters,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
January 2000, International archives of allergy and immunology,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
January 2002, Bioorganic & medicinal chemistry letters,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
February 1994, International immunology,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
September 1992, Journal of immunology (Baltimore, Md. : 1950),
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
September 1994, Mechanisms of development,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
September 1996, Immunology,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
February 1995, The Biochemical journal,
P Altevogt, and M Hubbe, and M Ruppert, and J Lohr, and P von Hoegen, and M Sammar, and D P Andrew, and L McEvoy, and M J Humphries, and E C Butcher
January 1995, Ciba Foundation symposium,
Copied contents to your clipboard!